Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity

Jurgen H. Runge 1 · Jet van Giessen 1 · Laura G. Draijer 2,3,4 · Eline E. Deurloo 1 · Anne M. J. B. Smets 1 · Marc A. Benninga 2 · Bart G. P. Koot 2 · Jaap Stoker 1

Received: 29 April 2020 / Revised: 16 July 2020 / Accepted: 28 August 2020 / Published online: 10 September 2020 © The Author(s) 2020

Abstract

Objectives To determine the diagnostic accuracy of controlled attenuation parameter (CAP) on FibroScan® in detecting and grading steatosis in a screening setting and perform a head-to-head comparison with conventional B-mode ultrasound.

Methods Sixty children with severe obesity (median BMI z-score 3.37; median age 13.7 years) were evaluated. All underwent CAP and US using a standardized scoring system. Magnetic resonance spectroscopy proton density fat fraction (MRS-PDFF) was used as a reference standard.

Results Steatosis was present in 36/60 (60%) children. The areas under the ROC (AUROC) of CAP for the detection of grade \(\geq S1\), \(\geq S2\), and \(\geq S3\) steatosis were 0.80 (95% CI: 0.67–0.89), 0.77 (95% CI: 0.65–0.87), and 0.79 (95% CI: 0.66–0.88), respectively. The AUROC of US for the detection of grade \(\geq S1\) steatosis was 0.68 (95% CI: 0.55–0.80) and not significantly different from that of CAP \((p = 0.09)\). For detecting \(\geq S1\) steatosis, using the optimal cutoffs, CAP (277 dB/m) and US (US steatosis score \(\geq 2\)) had a sensitivity of 75% and 61% and a specificity of 75% and 71%, respectively. When using echogenicity of liver parenchyma as only the scoring item, US had a sensitivity of 70% and specificity of 46% to detect \(\geq S1\) steatosis. The difference in specificity of CAP and US when using only echogenicity of liver parenchyma of 29% was significant \((p = 0.04)\).

Conclusion The overall performance of CAP is not significantly better than that of US in detecting steatosis in children with obesity, provided that the standardized scoring of US features is applied. When US is based on liver echogenicity only, CAP outperforms US in screening for any steatosis \((\geq S1)\).

Key Points

- The areas under the ROC curves of CAP and ultrasound (US) for detecting grade \(\geq S1\) steatosis were 0.80 and 0.68, respectively, and were not significantly different \((p = 0.09)\).
- For detecting grade \(\geq S1\) steatosis in severely obese children, CAP had a sensitivity of 75% and a specificity of 75% at its optimal cutoff value of 277 dB/m.
- For detecting grade \(\geq S1\) steatosis in clinical practice, both CAP and US can be used, provided that the standardized scoring of US images is used.

Jurgen H. Runge and Jet van Giessen contributed equally to this work.

Jurgen H. Runge and Jet van Giessen shared first authorship.

Laura G. Draijer
lg.draijer@amsterdamumc.nl

1 Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

2 Department of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Centers, Location Academic Medical Center/Emma Children’s Hospital, University of Amsterdam, Amsterdam, The Netherlands

3 Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Centers, Location Academic Medical Center/Emma Children’s Hospital, Amsterdam, The Netherlands

4 Amsterdam UMC, University of Amsterdam, Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, The Netherlands

Springer
Introduction

Due to the increasing prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in adults and children worldwide [1, 2]. The NAFLD spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. The pooled prevalence of NAFLD in children ranges from 7.6% in general population studies to 34.2% in studies based on child obesity clinics [1, 3, 4]. Although simple steatosis is the most common and benign stage in children, advanced fibrosis is reported in 17% of children with elevated alanine aminotransferase (ALT) referred from primary care to liver centers after screening [5]. In addition, NAFLD increases the risk of developing type 2 diabetes and cardiovascular diseases at adult age [6, 7]. Timely detecting and staging of NAFLD is therefore of great importance, particularly in children who might be at a higher risk of complications in their lifetime given their longer life span [8–10].

Screening for NAFLD in children with obesity is propagated in most national and international obesity and hepatology guidelines [11]. However, the advised screening tools in these guidelines, serum ALT and conventional B-mode ultrasound (US), have a poor accuracy for detecting and grading steatosis [5, 12–20]. Magnetic resonance techniques, including magnetic resonance spectroscopy proton density fat fraction (MRS-PDFF), have excellent accuracy and reproducibility for detecting and grading liver steatosis in adults and children [21–26]. MRS-PDFF has been accepted as a non-invasive reference standard for quantifying hepatic steatosis in studies [23, 27, 28]. These MR techniques are not suitable for screening in daily clinical practice due to relatively high costs and dependence on patient compliance, which can be a concern in the pediatric population. Therefore, an easy-to-use, inexpensive, and accurate screening tool for NAFLD is still very much needed.

In recent years, the controlled attenuation parameter (CAP) became available on the FibroScan® device (Echosens SA) for the detection of hepatic steatosis. CAP reflects the attenuation (loss of signal amplitude) of an ultrasound beam as it traverses tissue and is influenced by the amount of hepatic fat [29]. CAP uses standardized (controlled) settings, thereby minimizing user influence on the attenuation value. CAP is expressed as a number, whereas in conventional B-mode ultrasound, the grayscale values (which in part reflect the level of attenuation) are interpreted by an observer. These interpretations are subject to inter-observer variability. A second advantage of CAP is that FibroScan® simultaneously measures liver stiffness to assess fibrosis, which is of great benefit when evaluating children with NAFLD.

The aim of this study was to determine the diagnostic accuracy of CAP in (a) detecting and (b) grading hepatic steatosis in children with obesity in a screening setting using MRS-PDFF as the reference standard. As a secondary aim, we performed a head-to-head comparison of the accuracy of CAP and US in detecting steatosis in children with obesity.

Methods

Study design and patients

This prospective study was registered in the Dutch Trial Register (NL4155). Participants were recruited from the outpatient obesity clinics of two hospitals in The Netherlands (Slotervaart Ziekenhuis and Amsterdam UMC), during a 4-year study period between 2014 and 2018. In The Netherlands, all children with obesity grade 3 (“severe obesity”) or grade 1 or 2 obesity with elevated glucose levels are referred to obesity clinics for evaluation of metabolic complications. Inclusion criteria were age 8–18 years and obesity (BMI z-score > 2). The exclusion criteria were presence of a liver disease other than NAFLD (viral/autoimmune hepatitis, Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency), known focal liver lesion(s) in the right liver lobe (proven with histology results or imaging), use of steatogenic drugs, and contraindications for MRI. Patients were consecutively included. All participants underwent conventional B-mode US of the liver, CAP measurement on FibroScan®, and MRS-PDFF at our tertiary hospital after a fasting period of at least 6 hours. The measurements were obtained during one or two visits, depending on the availability of MRI, FibroScan®, and US. The study was approved by the Medical Ethics Committee of the Amsterdam UMC, location Academic Medical Center. Written informed consent was obtained from the participants aged 12 years or older and/or their

Keywords Elasticity imaging techniques - Non-alcoholic fatty liver disease - Child - Obesity
legal guardians. We followed the Standards for Reporting of Diagnostic Accuracy (STARD) guidelines in this study on the accuracy of CAP and US in detecting hepatic steatosis [30].

Sample size calculation

Sample size calculations were performed for both primary and secondary outcomes; as the secondary outcome required a larger sample size, this is given here. Bohte et al previously showed that US had a sensitivity of 85% (95% CI: 77–91) and a specificity of 55% (95% CI: 46–65) for detecting any degree of steatosis in children with obesity [12]. Based on studies performed in adults, we hypothesized that CAP would have a specificity at least 15% higher than US. Using a McNemar test, we calculated that 26 non-steatotic subjects were required to reach a significant difference in specificity between US and CAP. Given the expected prevalence of steatosis (diagnosed on MRS-PDFF) of 50% [12], a sample size of 52 subjects was anticipated required. After 40 subjects were included, interim analysis revealed a lower prevalence of non-steatotic subjects than anticipated (43%). The number of required subjects was thereupon increased to 60 to allow more non-steatotic subjects to be included. Regardless of the final prevalence, study inclusion was stopped after 60 subjects had completed all study procedures.

Clinical assessment

Physical examination included measurement of weight, height, body mass index (BMI), waist circumference, and blood pressure. The BMI z-score was calculated. The BMI z-score is the number of standard deviations (SD) from the mean on a standard BMI curve for age and gender. Children with a BMI z-score of > 2 (equals > 95th percentile) were considered to have obesity, and those with a BMI z-score of > 2.6 (equals > 99th percentile) were considered to have severe obesity [31, 32].

Laboratory tests

Alanine aminotransferase (ALT) levels were obtained from the patients’ clinical record. Values obtained within 3 months to the study visit were used for analysis. No blood was sampled for the purpose of this study.

| Score | Normal echogenicity of liver parenchyma | Slightly increased echogenicity of liver parenchyma | Markedly increased echogenicity of liver parenchyma | Severely increased echogenicity of liver parenchyma |
|-------|----------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 0     | Normal visualization of diaphragm and intrahepatic blood vessels | Normal visualization of diaphragm and intrahepatic blood vessels | Markedly increased echogenicity of liver parenchyma | Severely increased echogenicity of liver parenchyma |
| 1     | Markedly increased echogenicity of liver parenchyma | Slightly decreased visualization of diaphragm and intrahepatic blood vessels | Severely increased echogenicity of liver parenchyma | No or severely decreased visualization of diaphragm and intrahepatic blood vessels and posterior part of the right liver lobe |

| Demographic           |               |
|-----------------------|---------------|
| Age (years)           | 13.7 (12.1–16.1) |
| Female, n (%)         | 26 (43) |
| Ethnicity, n (%)      |               |
| Turkish               | 23 (38) |
| Caucasian             | 16 (27) |
| African               | 4 (7) |
| Surinamese            | 3 (5) |
| Asian                 | 3 (5) |
| North-African         | 2 (3) |
| Other/unknown         | 9 (15) |

| Clinical              |               |
|-----------------------|---------------|
| Steatosis, n (%)      | 36 (60) |
| BMI z-score           | 3.37 (3.01–3.98) |
| Waist circumference, cm (IQR) | 100 (90–121) |

| Biological data       |               |
|-----------------------|---------------|
| ALT, IU/L (IQR)       | 28 (19–39) |

| MRS-PDFF              |               |
|-----------------------|---------------|
| Fat fraction, % (IQR) | 5.90 (2.12–15.38) |
| S0, n (%)             | 24 (40) |
| S1, n (%)             | 21 (35) |
| S2, n (%)             | 7 (12) |
| S3, n (%)             | 8 (13) |

| Ultrasound             |               |
|-----------------------|---------------|
| US steatosis score 0, n (%) | 16 (27) |
| US steatosis score 1, n (%) | 15 (25) |
| US steatosis score 2, n (%) | 16 (27) |
| US steatosis score 3, n (%) | 13 (21) |

Continuous variables are expressed in median with interquartile range (IQR) in parentheses or n (%). ALT was measured in 40 patients. ALT alanine aminotransferase, BMI body mass index, MRS-PDFF magnetic resonance spectroscopy proton density fat fraction.
Reference test: proton density fat fraction with magnetic resonance spectroscopy

All subjects underwent an MRI scan after fasting, consisting of localizers and several anatomic imaging sequences followed by the MRS-PDFF sequence. Briefly, a single breath-hold, multi-echo stimulated echoes acquisition mode (STEAM) $^1$H-MRS sequence was performed using a $20 \times 20 \times 20$ mm$^3$ voxel positioned in segment VI or VII of the liver. Further details on acquisition and post-processing have been described in a previous study in our hospital. MRI technicians were blinded to clinical information and CAP and US results. Steatosis grades 1 (S1), S2, and S3 were defined as an MRS-PDFF fat fraction of $>4.14\%$, $>15.72\%$, and $>20.88\%$, respectively. These thresholds were validated to correspond with steatosis grades 1, 2, and 3 of the NAFLD Activity Score (NAS) based on liver histology in adults in a previous study in our hospital [33].

Index test 1: controlled attenuation parameter

The CAP measurement was obtained using the FibroScan® 502 Touch Device with the 3.5-MHz M-probe. CAP was measured intercostally, in a midaxillary location, by one of two observers (J.R., a radiology resident who has performed more than 100 examinations, and B.K., a pediatric gastroenterologist who has performed more than 400 examinations). Both observers were blinded to US and MRS-PDFF results. Only CAP results with at least 10 valid measurements were analyzed.

Index test 2: conventional B-mode ultrasound

The US assessment was performed using the ATL HDI 5000 IU22 and Epiq 5G (Philips Healthcare) equipped with 5-2 and 9-2 curved-array transducers. US was performed by one of two pediatric radiologists with 10 and 30 years of experience in pediatric US. Both were blinded to any other result. The “abdominal general” setting was used and gain and focus were manually adjusted, depending on patient habitus and beam attenuation. The following standardized views of the liver were obtained: transverse and longitudinal views of the right hepatic lobe, including the right kidney and diaphragm; a sagittal view of the left liver lobe; a view including the portal vasculature; and a view of the gallbladder region. To assess steatosis, the following four widely accepted items were evaluated by the radiologists: echogenicity of liver parenchyma, visualization of diaphragm, visualization of intrahepatic vessels, and visualization of posterior part of the right hepatic lobe [34]. Ultrasonic images of these features were previously shown by Bohte et al [12]. A final qualitative score from 0 to 3 was given by the radiologists with respect to liver steatosis: the “ultrasound steatosis score” (US steatosis score; Table 1) [12]. We calculated the optimal US steatosis score to separate grade S0 steatosis from S1–S3, S0–S1 from S2–S3, and S0–S2 using the Youden index that maximizes sensitivity and specificity.

We applied these optimal US steatosis scores to determine the accuracy of US in detecting ≥S1, ≥S2, and ≥S3. In clinical practice, steatosis is often assessed based only on increased liver echogenicity, without taking other features into account. Therefore, we additionally determined the accuracy of US when using echogenicity of liver parenchyma as only scoring item and compared this with CAP.

Statistical analysis

Descriptive statistics were used to analyze patients’ demographic, laboratory, and imaging data. We calculated the optimal cutoff value for CAP to separate grade S0 steatosis from S1–S3, S0–S1 from S2–S3, and S0–S2 from S3 using the Youden index. The diagnostic accuracy of CAP and US for grading steatosis was calculated, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratios (LR+, LR−), and receiver operating characteristic (ROC) curve with 95% confidence intervals. We compared the areas under the ROC curves (AUROC) of CAP and US using a (pairwise) comparison according to the method used by Hanley and McNeil [35]. We compared sensitivity and specificity of CAP and US in detecting ≥S1 steatosis using the McNemar chi-square test. A value of $p < 0.05$ was considered a statistically significant difference. Statistical analyses were performed by using software (SPSS, version 22 [IBM]; GraphPad Prism 8.0 [GraphPad Software]; MedCalc.
Results

Sixty-two participants (34 males, 28 females) were consecutively included between October 2014 and December 2018. One participant refused MRI measurement and in one patient CAP measurement failed, most likely due to a large waist circumference. Patient characteristics are summarized in Table 2. The median age was 13.7 years (IQR 12.1–16.1). Median BMI z-score was 3.37 (IQR 3.01–3.98). Most participants were of Turkish or Dutch descent (38% and 27%, respectively). The median interval between MRS-PDFF and the index tests was 0 days (IQR 0–4). Hepatic steatosis, defined as an MRS-PDFF fat fraction of >4.14%, was present in 36/60 children (60%). Grade 2 steatosis was found in 7 patients and 8 patients had grade 3 steatosis based on MRS-PDFF.

CAP versus ultrasound

CAP and US were successfully obtained in 60 patients. Median CAP value was 253 dB/m (IQR 218–287) in children without steatosis versus 327 dB/m (IQR 272–368) in children with steatosis. The scatterplot in Fig. 1 shows the logarithmic relationship between CAP and MRS-PDFF. Figure 2 shows

Fig. 2 Box-and-whisker plot. Box-and-whisker plot of CAP according to steatosis grade at MRS-PDFF. Boxes show median and 25th and 75th percentiles, and whiskers show minimum and maximum values. Horizontal brackets indicate significant differences between steatosis grades. CAP controlled attenuation parameter, MRS-PDFF magnetic resonance spectroscopy proton density fat fraction.

Fig. 3 Comparison of ROC curves. Comparison of ROC curves for three cutoffs. a Grade S0 steatosis versus grades S1–S3. b Grades S0–S1 versus S2–S3. c Grades S0–S2 versus S3. Black and gray lines indicate CAP and US, respectively. Optimal cutoffs are calculated using the Youden index. AUROC area under the ROC curve, CAP controlled attenuation parameter, ROC receiver operating curve, US ultrasound.
Table 3  Diagnostic accuracy of CAP and US

|     | AUROC  | Cutoff        | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | LR+ (95% CI) | LR− (95% CI) |
|-----|--------|---------------|------------------------|------------------------|---------------|---------------|--------------|--------------|
| CAP | S0 versus S1-3 | 0.795 (95% CI: 0.671–0.888) | > 277 dB/m | 75.0 (57.8–87.9) | 75.0 (53.3–90.2) | 81.8 (68.7–90.2) | 66.7 (52.1–78.7) | 3.00 (1.46–6.15) |
|     | S0–1 versus S2–3 | 0.774 (95% CI: 0.648–0.872) | > 294 dB/m | 80.0 (51.9–95.7) | 64.4 (48.8–78.1) | 42.9 (32.0–54.5) | 90.6 (77.4–96.5) | 2.25 (1.41–3.59) |
|     | S0–2 versus S3 | 0.787 (95% CI: 0.662–0.882) | > 349 dB/m | 75.0 (34.9–96.8) | 84.6 (71.9–93.1) | 42.9 (26.1–61.4) | 95.7 (86.8–98.7) | 4.88 (2.30–10.35) |
| US  | S0 versus S1-3 | 0.683 (95% CI: 0.550–0.797) | US score ≥ 2 | 61.1 (43.5–76.9) | 70.8 (48.9–87.4) | 44.4 (34.3–55.8) | 93.6 (79.7–98.2) | 2.44 (1.57–3.79) |
|     | S0–1 versus S2–3 | 0.801 (95% CI: 0.678–0.931) | US score ≥ 2 | 86.7 (59.5–98.3) | 64.4 (48.8–78.1) | 44.4 (34.3–55.8) | 93.6 (79.7–98.2) | 2.44 (1.57–3.79) |
|     | S0–2 versus S3 | 0.808 (95% CI: 0.685–0.898) | US score ≥ 3 | 75 (34.9–96.8) | 86.5 (74.2–94.4) | 46.2 (27.9–65.5) | 95.7 (87.1–98.7) | 5.57 (2.51–12.36) |

Diagnostic accuracy of CAP and US to detect grade ≥ S1, ≥ S2, and ≥ S3 steatosis at their optimal cutoff values, determined using the Youden index. AUROC area under the ROC curve, CAP controlled attenuation parameter, LR+ positive likelihood ratio, LR− negative likelihood ratio, NPV negative predictive value, PPV positive predictive value, US ultrasound.

Discussion

This study reports on the accuracy of CAP and conventional B-mode US for detecting steatosis in children with obesity. The overall performance of CAP was not significantly better than that of US. When using only echogenicity of liver parenchyma of 29%, CAP had a sensitivity of 75% and a specificity of 75% (Table 3). At its optimal cutoff value (US score ≥ 2), US had a sensitivity of 71% for detecting ≥ S1 steatosis.

Based on the Youden index, the optimal cutoff value for CAP was 277 dB/m, yielding a sensitivity of 61% and a specificity of 66%. When using only echogenicity of liver parenchyma of 29%, the difference in sensitivity between CAP and US for detecting ≥ S1 steatosis was significant (p = 0.04). The optimal diagnostic accuracy of CAP and US to detect different stages of steatosis (S0 ≥ S1, ≥ S2, ≥ S3) is fully established at 1.5% (measured by 1H-MRS), and is not associated with the histological severity of liver disease.
which is well below the current cutoff point for the diagnosis of NAFLD [37].

Comparing the accuracy data from this study to those from previous studies is difficult as study populations and reference standards differ among studies. The performance of CAP for detecting ≥ S1 steatosis, reflected in the area under the ROC curve (0.80; 95% CI: 0.67–0.89), is comparable to that of adult studies: 0.85 in a meta-analysis in 2014 [38] and 0.77–0.96 in recent studies [33, 39–44]. In comparison to pediatric studies, Ferraioli et al found an AUROC of 0.84 (95% CI: 0.78–0.89) to detect ≥ S1 steatosis in a mixed population of children with and without obesity [45]. However, US was used as the reference standard which is less accurate than MRS-PDFF. Desai et al reported a higher performance of CAP: AUROC of 0.93 (95% CI: 0.87–0.99) and a sensitivity of 87% and specificity of 83% in detecting ≥ S1 steatosis at the optimal cutoff point, using biopsy as the reference standard [46]. This difference may be accounted to the difference in study population, as they included children with various liver diseases; only 14 out of 69 had NAFLD, and mean BMI z-score was 0.67 compared with a median BMI z-score of 3.51 in our study. Shin et al evaluated 86 children with and without obesity and also reported a higher accuracy of CAP: AUROC 0.94 (95% CI: 0.87–0.98) and a sensitivity of 99% and specificity of 80% in detecting ≥ S1 steatosis using MRI-PDFF as the reference standard [47]. Again the difference in BMI might explain the difference in performance, since only 17/83 children had severe obesity versus all children in our study. In agreement with our results, they found that discrimination between S1, S2, and S3 steatosis was suboptimal.

Thus far, different optimal CAP thresholds have been found in studies. In our study, a threshold of 277 dB/m was found to be most optimal to detect ≥ S1 steatosis which is comparable to the proposed thresholds from adult studies that range between 236 dB/m and 302 dB/m [33, 39, 40, 42, 43, 48]. This threshold is higher compared with the pediatric studies by Desai et al [46] and Shin et al [47]: 225 dB/m and 241 dB/m, respectively. The latter could be explained by the different study populations and underlying disorders, since in adults CAP values have been found to be significantly associated with BMI, waist circumference, and the studied liver disease, including higher values in NAFLD [41]. This implies that disease- or patient-group-specific thresholds are required. The threshold determined in this study needs validation in another population-based cohort of children with obesity.

To ensure a fair comparison between the accuracy of CAP (continuous variable) and US (categorical variable) in detecting ≥ S1 steatosis, we used the optimal thresholds for the detection of ≥ S1 steatosis of both tools. The US threshold in this study (US score ≥ 2) is in line with the previous reported pooled accuracy results of US [11]. In our study, CAP had a 14% higher sensitivity compared with US. This difference was not significant as our study was powered on detecting a difference of 15% in specificity in a cohort with lower anticipated prevalence of steatosis. To determine whether there is a small difference in accuracy between CAP and US, a larger study is needed. For clinical practice, this study implies that both CAP and US can be used for screening purposes depending on local availability and expertise.

When using ultrasound in clinical practice, steatosis is often considered present when only liver echogenicity is increased, and other US features (e.g., decreased visibility of intrahepatic vessels, decreased visualization of the diaphragm) are less frequently used or specifically mentioned in radiological reports. We found that when taking only liver echogenicity into account, specificity of CAP was 29% higher (p = 0.04). These findings underscore the relevance of evaluating more than just the increased echogenicity of the liver parenchyma when using US in children suspected to have steatosis.

The strength of this study is the use of MRS-PDFF as the reference standard as it has high accuracy in detecting and grading steatosis. In addition, the MRS-PDFF setting used in this study has been validated compared with histology [33]. Validation was performed in adults since validation with histology in a pediatric cohort of NAFLD is unfeasible due to ethical objections. Another strength is the inclusion of a multi-ethnic study population which is representative of the population targeted for NAFLD screening. This study therefore evaluates the usefulness of CAP and US in a setting identical to the real-life screening situation. A limitation of the current study is its sample size and the low number of children with higher steatosis grades, hampering the comparison of accuracy of CAP and US in grading steatosis. Also, we were not able to correlate CAP with metabolic factors, as no blood was drawn for the purpose of this study.

In conclusion, this study shows that CAP has a sensitivity and a specificity of both 75% at the optimal threshold of 277 dB/m. However, the overall performance of CAP compared with US for detecting steatosis in children with obesity is not significantly better, provided that the standardized scoring of US images is used. When US is based on liver echogenicity only, CAP had a 29% higher specificity and thereby outperforms US in detecting steatosis.

Funding The authors state that this work has not received any funding.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Jaap Stoker.

Conflict of interest The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry Several authors have significant statistical expertise. Therefore, statistical advice was not needed for this manuscript.
Informed consent: Written informed consent was obtained from all subjects (patients) and legal guardians in this study.

Ethical approval: Institutional Review Board approval was obtained.

Methodology:
- prospective
- diagnostic study
- performed at one institution

Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References:

1. Wong RJ, Aguilar M, Cheung R et al. (2015) Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148:547–555
2. Nobili V, Reale A, Alisi A et al. (2009) Elevated serum ALT in children and adolescents: a systematic review and meta-analysis. PLoS One 10:e140908
3. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. (2015) The prevalence of non-alcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 54:704–713
4. Vajro P, Lenta S, Socha P et al. (2012) Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 54:704–713
5. Schwimmer JB, Newton KP, Awai HI et al. (2013) Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther 38:1267–1277
6. Hecht L, Weiss R (2014) Nonalcoholic fatty liver disease and type 2 diabetes in obese children. Curr Diab Rep 14:448
7. Armstrong MJ, Adams LA, Canbay A, Syn WK. (2014) Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59:1174–1179
8. Feldstein AE, Charatcharoenwitthaya P, Teerprasertsuk S, Benson JT, Enders FB, Angulo P (2009) The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58:1538–1544
9. Molleston JP, White F, Teckman J, Fitzgerald JF (2002) Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 97:2460–2462
10. Alkhouri N, Hanouneh IA, Zein NN et al. (2016) Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int 29:418–424
11. Koot BGP, Nobili V (2017) Screening for non-alcoholic fatty liver disease in children: do guidelines provide enough guidance? Obes Rev. https://doi.org/10.1111/obr.12556
12. Bohte AE, Koot BG, van der Baan-Slootweg OH et al. (2011) US cannot be used to predict the presence or severity of hepatic steatosis in severely obese adolescents. Radiology 262(1):327–334
13. Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A (2007) MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 96:542–547
14. Pozzato C, Radaelli G, Dall’Asta C et al. (2008) MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. J Pediatr Gastroenterol Nutr 47:493–499
15. Shannon A, Alkhouri N, Carter-Kent C et al. (2011) Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr 53:190–195
16. Radetti G, Kleon W, Stuefer J, Pittschiefer K (2006) Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr 95:833–837
17. Burgert TS, Taksali SE, Dziura J et al. (2006) Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 91:4287–4294
18. Rehm JL, Connor EL, Wolfgam PM, Eickhoff JC, Reeder SB, Allen DB (2014) Predicting hepatic steatosis in a racially and ethnically diverse cohort of adolescent girls. J Pediatr 165:319–325.e311
19. Molleston JP, Schwimmer JB, Yates KP et al. (2014) Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 164:707–713.e703
20. Draijer LG, Feddouli S, Bohte AE et al. (2019) Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric non-alcoholic fatty liver disease. Eur J Pediatr. https://doi.org/10.1007/s00431-019-03362-3
21. Bohte AE, van Werven JR, Bipat S, Stoker J (2011) The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 21:87–97
22. Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB (2014) Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol 12:765–773
23. Di Martino M, Pacifico L, Bezzì M et al. (2016) Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. World J Gastroenterol 22:8812–8819
24. Schwimmer JB, Middleton MS, Behling C et al. (2015) Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology 61:1887–1895
25. Middleton MS, Van Natta ML, Heba ER et al. (2018) Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology 67:858–872
26. Rehm JL, Wolfgam PM, Hernando D, Eickhoff JC, Allen DB, Reeder SB (2015) Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women. Eur Radiol 25:2921–2930
27. Noreuddin M, Lam J, Peterson MR et al. (2013) Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58:1930–1940
28. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402
29. Sasso M, Miette V, Sandrin L, Beaugrand M (2012) The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 36:13–20
30. Bossuyt PM, Reitsma JB, Bruns DE et al (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351:h5527
31. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320:1240–1243
32. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP (2000) Body index measurements in 1996-7 compared with 1980. Arch Dis Child 82:107–112
33. Runge JH, Smits LP, Verheij J et al (2018) MR spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis. Radiology 286:547–556
34. Saverymuttu SH, Joseph AE, Maxwell JD (1986) Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292:13–15
35. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843
36. Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL (2014) Nonalcoholic fatty liver disease: different classifications concor-dance and relationship between degrees of morphological features and spectrum of the disease. Anal Cell Pathol (Amst) 2014:526979
37. Bril F, Barb D, Portillo-Sanchez P et al (2017) Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology 65:1132–1144
38. Shi KQ, Tang JZ, Zhu XL et al (2014) Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 29:1149–1158
39. Eddowes PJ, Sasso M, Allison M et al (2019) Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156:1717–1730
40. Imaio K, Kessoku T, Honda Y et al (2016) Magnetic resonance imaging more accurately classifies Steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150:626–637.e627
41. de Ledinghen V, Vergniol J, Capdepont M et al (2014) Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 60:1026–1031
42. Baumeler S, Jochum W, Neuwieder J, Bergamin I, Semela D (2019) Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience. Swiss Med Wkly 149:w20077
43. Caussy C, Alquirais MH, Nguyen P et al (2018) Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology 67: 1348–1359
44. Pu K, Wang Y, Bai S et al (2019) Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol 19:51
45. Ferraioli G, Calcatera V, Liassandrin R et al (2017) Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. BMC Gastroenterol 17:61
46. Desai NK, Harney S, Raza R et al (2016) Comparison of controlled attenuation parameter and liver biopsy to assess hepatic steatosis in pediatric patients. J Pediatr 173:160–164.e161
47. Shin J, Kim MJ, Shin HJ et al (2019) Quick assessment with controlled attenuation parameter and liver biopsy to assess hepatic steatosis in children based on MRI-PDFF as the gold standard. BMC Pediatr 19:112
48. Karlas T, Petroff D, Sasso M et al (2017) Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 66:1022–1030

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.